For the year ending 2024-12-31.
| Income Statement | 2024-12-31 | |||
|---|---|---|---|---|
| Research and development-Nonrelated Party | 1,840,081 | |||
| Research and development-Related Party | 58,000 | |||
| General and administrative | 1,942,163 | |||
| Total operating expenses | 3,840,244 | |||
| Loss from operations | -3,840,244 | |||
| Interest expense-Nonrelated Party | 126,476 | |||
| Interest expense-Related Party | 651,910 | |||
| Interest expense - amortization of debt discount-Nonrelated Party | 156,221 | |||
| Interest expense - amortization of debt discount-Related Party | 153,693 | |||
| Change in fair value of derivative liabilities-Nonrelated Party | 353,174 | |||
| Change in fair value of derivative liabilities-Related Party | 44,835 | |||
| Gain on extinguishment of note payable | 17,893 | |||
| Total other expense | -672,398 | |||
| Net loss | -4,512,642 | |||
| Dividend attributable to series a, b, and c preferred stockholders | 1,375,188 | |||
| Net loss applicable to common stockholders | -5,887,830 | |||
| Basic EPS | -0.14 | |||
| Diluted EPS | -0.14 | |||
| Basic Average Shares | 41,870,597 | |||
| Diluted Average Shares | 41,870,597 | |||
Cell Source, Inc. (CLCS)
Cell Source, Inc. (CLCS)